Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Xilio Therapeutics Inc

XLO ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$9.17

▲ +1.78%

Market Cap $60.34M · Vol 2.13K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$60.34M

Micro Cap

Div Yield

N/A

EPS Growth

+27.92%

YoY

RSI (14)

53.88

Momentum

Beta

-0.05

vs Market

52W High

$12.68

27.66% below

52W Low

$6.62

38.54% above

Volume

2.13K

Avg 8.24K

P/B

0.08

Price-to-book

ROE

N/A

Return on equity

Free Float

57.83%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Xilio Therapeutics Inc (XLO) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XLO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.66%

+1.55%

+4.09%

+12.89%

YTD

+2.31%

-6.79%

-76.01%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$43.77M
Net Income	$-35,036,000.00
Revenue Growth (YoY)	+131.22%
Gross Margin	100.00%
Operating Margin	-95.92%
Net Profit Margin	-80.05%
ROE	N/A
ROA · ROIC	-31.04% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.12
P/B	0.08
P/FCF	N/A
EPS Growth	+27.92%
Outstanding Shares	6.58M

Technical Indicators

50-Day SMA	$8.86
200-Day SMA	$8.84
RSI (14)	53.88
Beta	-0.05
52-Week High	$12.68
52-Week Low	$6.62

Volume Today	2.13K
Avg Daily Volume (30D)	8.24K
Relative Volume	0.26x
Volatility (10D)	17.97
Volatility (30D)	30.09
Free Float	57.83%

Analyst Consensus

STRONG BUY

Current Price $9.17

Mean Target $20.00

52W Low$6.62 52W High$12.68

Current

Target

$6.62 $12.68

Current Analyst target

+118.10% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00M4D4XC8

ISINUS98422T2096

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.